Skip to Content
Search Menu

AML Insights – June Update: What’s New in the Field

Discover the key developments in the treatment of acute myeloid leukemia, including advances in CAR-T cell and NK cell therapies, new combination regimens such as venetoclax with hypomethylating agents, and targeted chemotherapy using anti-CD33 antibodies.
Don’t miss these exciting developments!

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Arsenic Trioxide-Induced Oral Manifestations: A Case of Vallate Papillae Swelling

/ Harisankar Anantharajan / Peter Bjerring / Luit Penninga / Carsten Sauer Mikkelsen
AML

Nordic AML Insights – June Update: Research and EHA Congress

/ Jan Andreasen
AMLAML higlights
Carl Sandén

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Carl Sandén
AMLEHA25 Play the Video 01:47
Justinas Daraskevicius

EHA 2025: Overcoming Venetoclax Resistance

/ Justinas Daraskevicius
AMLEHA25 Play the Video 02:20
Anne Louise Tølbøll Sørensen

EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

/ Anne Louise Tølbøll Sørensen
AMLEHA25 Play the Video 03:03

Nordic AML Insights: Research and Ph.D. Contributions

/ Jan Andreasen
AMLAML higlights

AML Insights: What’s New in the Field

/ Jan Andreasen
AMLAML higlights
Michael Savona

AML: Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine

/ Michael Savona
AMLLeukemia Play the Video 08:00

Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment

/ Andrea Lenartova / Jan Andreasen
AML
Back to top